Effect of Simvastatin on Pneumonia Prognosis in Elderly Patients: A Study of Immunological, Inflammatory, and Coagulation Responses in Relation to Reduce Mortality During Hospitalization
Elderly patients diagnosed with pneumonia after getting information and signing informed
consent will be included in this trial. Simvastatin 20 mg will be administered to
intervention group, while control group will receive placebo. Both groups will receive drugs
(or placebo) for 30 days.
Baseline data will be collected within 24 hours after admission. Then the subject will be
followed up for 30 days. At the 7th day, patients will be underwent several laboratory
tests, i.e. serum TNF-α (Tumor Necrosis Factor alpha), IFN-ϒ Interferon gamma), CRP
(C-Reactive Protein), and PAI-1 (Plasminogen Activator Inhibitor-1). Death from all causes
until 30 days will be recorded.
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Kuntjoro Harimurti, MD, MSc
Department of Internal Medicine, Cipto Mangunkusumo Hospital, Faculty of Medicine University of Indonesia
Indonesia: Departement Kesehatan (Department of Health)